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Abstract: Bone adaptation or integration of an implant is characterized by a series of 
biological reactions that start with bone turnover at the interface (a process of localized 
necrosis), followed by rapid repair. The wound healing response is guided by a complex 
activation of macrophages leading to tissue turnover and new osteoblast differentiation on 
the implant surface. The complex role of implant surface topography and impact on healing 
response plays a role in biological criteria that can guide the design and development of 
future tissue-implant surface interfaces.  
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1. Introduction 
Endosseous dental implants have created a revolution in the routine approach to dental care for 
patients missing one or more teeth. The clinical success for this procedure occurs through a series of 
clinical and biological steps starting with initial primary stability provided by the amount, quality and 
distribution of bone within the proposed implant site [1]. Following placement of the dental implant a 
series of bone modeling and remodeling steps take place. Bone adaptation or integration of an implant 
is characterized by a series of biological reactions that start with bone turnover at the interface (a 
process of localized necrosis), followed by rapid repair [2]. The common clinical end point of this 
process is measured by a lack of signs and symptoms of aggressive chronic inflammation, a lack of 
mobility and a radiographic assessment of bone adapted to the interface [3,4]. While high success rates 
hold for certain anatomic regions, the bony response within the thin cortical plates and diminished 
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cancellous bone characterizing the Lekhom and Zarb type IV bone is considerably less successful 
(e.g., 65–85%) with conventional machined surfaced implants [5]. These results may relate to both the 
minimally rough implant surfaces being used at the time of Lindh’s study and the patient population 
assessed. The response of trabecular bone to the mechanical environment is a critical factor, especially 
in regions of the jaw, such as the edentulous posterior maxillae, where the cortical thickness and/or 
local material properties are insufficient to withstand occlusal forces [2].  
The long-term success of implant therapy is not just dependant on enhanced osseous stability. More 
recently, there is greater attention being addressed to the transmucosal dental implant or implant 
abutment interfaces. The mechanical and biological stability derived from the design and surfaces in 
this connective tissue and junctional epithelial environment are critical to maintaining a sufficient 
volume of connective tissue with minimal inflammatory infiltrate. Chronic inflammation in this 
transmucosal region can be influenced by the designs, materials or surface roughness leading to long-
term tissue recession and even peri-implantitis years after the completion of tooth replacement 
therapy [6–13]. In order to increase the predictability of implant therapy, significant efforts have gone 
into development of implant biomaterials that hold the promise of improving clinical success. These 
technologies have evolved from simple modification of the oxide surface to precise nano-scale 
modification technologies that involve the formation of a uniform and consistent surface that leads to 
altered cellular response. Further, there are developing technologies to utilize changes in surface 
chemistry or even potentially biologics being added to the oxide surface to assist in stability of both 
the osseous and transmucosal environment. 
The purpose of this review is to discuss some of the recent developments in titanium implant 
surface technology and to discuss the role in mediating macrophage biology in the wound healing site 
around the implant. 
2. Implant Macro-Retentive Features 
Implants used in the oral environment have one of three major types of macro-retentive features: 
screw threads (tapped or self tapping), solid body press-fit designs and/or sintered bead technologies. 
These approaches are designed to enhance initial implant stability and/or create large volumetric 
spaces for bone in-growth. An important biological principal of bone is that it responds favorably to 
compressive loading (without the presence of a ligament) but not to shear forces [14]. Therefore, screw 
thread implant designs have been adapted to achieve a compressive loading of the surrounding cortical 
or cancellous bone. Other thread designs focus on reducing the surrounding shear forces by reducing 
the height of the thread profile (reducing the contribution of any one thread) with an increase in the 
number of threads per unit area of the implant surface  [15]. This has the additional benefit of 
increasing the strength of the implant body by increasing the amount of remaining wall thickness of 
the implant body [16]. Finally, orthopedic prosthesis (e.g., femoral stems, pelvic acetabular caps, knee 
prosthesis, etc.) have used various sintering technologies to create mesh or sintered beads as a surface 
for bone to grow in to. The application of this technology to dental implants has involved attempts to 
improve the success rate of short implants (<10 mm in length) [17]. This has been applied to a limited 
number of dental implant systems with very short implants [18–26]. Int. J. Mol. Sci. 2010, 11                 
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3. Implant Micro-Retentive Features 
Upon the placement of an implant into a surgical site, there is a cascade of molecular and cellular 
processes that provide for new bone growth and differentiation along the biomaterial surface. 
Following placement, the surrounding bone undergoes an initial necrosis, bone resorption and 
replacement, initially with a woven-like cell rich bone that is replaced through remodeling with mature 
haversian bone [27,28]. The goal of a number of current strategies is to provide an enhanced osseous 
stability through micro-surface mediated events. These strategies can be divided into those that attempt 
to enhance the in-migration of new bone (e.g., osteoconduction) through changes in surface 
topography (a.k.a., surface roughness), biological means to manipulate the type of cells that grow onto 
the surface and strategies to utilize the implant as a vehicle for local delivery of a bioactive coating 
(adhesion matrix or growth factor such as BMP-2) [29,30].  
One means to improve implant success is through methods to increase the amount of bone contact 
along the body of the implant. While it may seem obvious that increased surface roughness of implants 
leads to greater success it is not clear what aspect of “roughness” is advantageous [31]. In dental 
implant design, it is assumed that a greater surface area (per unit of bulk metal surface) is an objective 
by various means to enhance the surface roughness of the implant surface. This enhanced surface area 
allows a greater area for load transfer of bone against the implant surface  [32–35]. It should be 
clarified that surface roughness is often a poorly described characteristic  [36]. Micromechanical 
features influence the process of secondary integration (bone growth, turnover and remodeling) [2]. 
One advantage of acid etching, a technique commonly used is to increase the roughness of the grit 
blasted surface creates the potential for a nanometer-scale topography on top of the macroscale 
roughness allowing bone to adapt to the surface under elevated shear forces [37,38]. Implant design 
features conventionally were thought to need surface pores or “pits” of 100 µm or greater in diameter 
for in growth of bone although clinically relevant surface roughness may actually be much finer (on 
the nanoscale level) [39].  
4. Implant Wound Healing and the Potential Role of Surface Modification 
Wound healing around a dental implant placed into a prepared osteotomy follows three stages of 
repair. Initial formation of a blood clot occurs through a biochemical activation followed by a cellular 
activation and finally a cellular response. As our understandings of these complex pathways are 
incomplete, there have been many approaches, especially in vitro systems, to tease apart the pathways. 
In doing this, it should be pointed out to the reader that most of our understanding of wound healing 
pathways extends from in vitro studies and this limits our understanding of both the redundancy of 
responses in situ as well as the potential validity of some observations made, in vitro.  
These initial rapid changes during the surgical phase of implant therapy leads to activation of key 
biochemical pathways: the clotting system (fibrinogen to fibrin), complement activation, Kinin 
cascade activation (vascular dilation) and finally, plasmingen activation of plasmin. The adhesion of 
platelets to the assembled fibrin scaffold as well as adhesion to the surface topography of an implant 
surface leads to a process of platelet activation. Platelets are a rich source of locally released growth 
factors (e.g., PDGF, TGF-Beta, PDEGF, IGF-1) that accelerate the wound healing process though Int. J. Mol. Sci. 2010, 11                 
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recruitment and differentiation of mesenchymal cells critical to establishing an osseous interface at the 
implant surface [40]. It is the interaction with the surface and serum proteins which appear to create 
the primary effect of implant surface topography [41]. Titanium surfaces that were modified though a 
controlled etching process have been shown to alter whole blood derived platelet adhesion and 
generated thrombin-antithrombin complexes [42]. Platelet activation has also been elevated on etched 
titanium surfaces. When platelet adhesion and activation was compared on machined versus 
blasted/etched titanium surfaces, in vitro, the smoother machined surfaces demonstrated higher 
adhesion of platelets but reduced activation while the rougher surfaces demonstrated reduced platelet 
adhesion but near 100% platelet degranulation [43].  
During the initial remodeling steps, there are a number of immune cells that mediate early tissue 
(platelets, PMNs) followed by an in migration of phagocyte macrophages  [44]. The complex and 
pluripotent role of macrophages has recently become engaged in biomaterials research not just as 
mediators of debris removal but also potentially playing a key role in mediating new bone formation 
on the implant surface [45,46]. Recent comprehensive reviews have articulated the complex role of 
macrophages and the conventional separation into the “classically activated macrophage pathway” 
(e.g., bacterial derived lipopolysaccaride or LPS) leading to activated Toll-like receptors relative to the 
“alternative macrophage activated pathway” (activation via IL-4, IL-13 and cell surface expression of 
mannose receptor (CD206) and Arginase-1 receptor) does not represent the current understanding of 
the phenotypic flexibility of this cell type. Mosser and Edwards suggest there is a continuum between 
these two cell types of macrophages and that wound healing is an important role of a subset of these 
cells [44]. An initial role for these cells is to remove the necrotic debris created by the drilling process 
and this material is laced with DNA fragments, histones, nuclear proteins and heat-shock proteins all 
of which leads to physiological changes in the macrophages, leading in turn to expression of cell 
surface proteins (CD135) production of cytokines and pro-inflammatory mediators though the NFΚB 
pathway [44,47]. Dental implants are typically placed from a cortical surface of the dental alveolus 
though into the medullar cavity. It is interesting to note that when histological studies are performed on 
clinically healed implants, there is often bone contact exceeding 50% of the implant surface area 
extending along the portion of the device that passes though the medullar cavity whereas this does not 
occur in the absence of the medical device [48–51]. This allows rapid contact of the implant surface 
with marrow derived monocytes and may be one reason for the observation of extensive adhesion of 
macrophages to retrieved implant surfaces [45]. The following steps are not fully understood and may 
involve interactions of inflammatory mediators on activating these cells into tissue-macrophages. 
Activation of macrophages typically involves a combination of tumor-necrosis factor alpha (TNF-α) 
and interferon-γ (IFNγ) to promote a bactericidal phenotype (e.g., expression IL-1, IL-6 and IL-23) 
initially though an innate immune response [44]. From a biomaterials perspective, the influence on the 
wound healing capacity by macrophages may be strategic. These cells respond though both innate and 
adaptive responses which includes response to basophil and mast cell release of IL-4 eliciting a 
differentiation of macrophages into a wound healing pathway [52, 53]. Later, adaptive immune 
response occurs though TH2 helper cell and IL-10 expression leading to expression from an 
intermediate regulatory macrophage of IL4 and IL-13. This cytokine-regulated cellular recruitment, 
migration, proliferation and formation of an extracellular matrix on the implant surface can be 
influenced by this early population of macrophages. These cells express growth factors such as Int. J. Mol. Sci. 2010, 11                 
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fibroblast growth factor (FGF-1, FGF-2, FGF-4), Transforming growth factors, epithelial growth 
factor as well as bone morphogenetic proteins (BMPs) [54,55]. The end result of this complex cascade 
is promotion of a wound healing process that includes angiogenesis. The development of an elaborate 
vascular network is an important part of the implant wounding healing process and may be elicited by 
the initial ischemia in the immediate wound site followed by the macrophage mediated release of 
bFGF, TNF-α and vascular endothelial growth factor (VEGF) [55–57]. 
The role of macrophages in implant topography has primarily focused more on polymer-based 
materials and the potential for inflammation in vascular-based devices. Macrophages are extensively 
involved in the complex process of aseptic necrosis in orthopedic applications which is primarily a 
response to polymer wear debris in the enclosed area of the implant site [58]. Dental implants typically 
have the part of the implant subject to wear being located within the oral cavity thus reducing the 
potential for macrophage-based activation to remove wear particles  [59–61]. Recent work has 
demonstrated though that macrophage activation is influenced by surface topography of the 
biomaterial. Paul et al., (2008) demonstrated topographical control using a polyvinylididene fluoride 
(PVDF) surface created using laser ablation and showed that macrophage responded to macroscopic 
surface topography in which they adhere and spread but not to nanoscale surface features and most 
intriguing was that specifically the CD163 positive macrophages (those associated with the alternative 
activation cascade or M2 cells in the conventional classification of macrophages) leading to a 
suggestion that the inflammatory response to implant surfaces can downregulate the expression of  
pro-inflammatory cytokines and thus implant topography can play a role in early events in 
biocompatibility [62]. 
The subsequent formation of a mineralized matrix during osteogenesis and bone remodeling or 
during osseointegration of dental implants involves the recruitment of multipotent mesenchymal stem 
cells and the progressive differentiation of these cells into osteoblasts [63]. Osteoblast differentiation 
and skeletal formation during embryonic development is mediated by an essential transcription factor 
protein called core binding-factor-alpha (Cbfa1) or RUNX-2 [64]. Cbfa1 belongs to the Runt family of 
transcription factors [65], and regulates osteoblast differentiation and expression of bone extracellular 
matrix protein genes that encode for bone sialoprotein (BSP), Osteocalcin and Type I 
Collagen [66,67]. RUNX-2/Cbfa1 plays an essential role in osteogenesis, osteoblast matrix formation, 
chondrocyte differentiation, and bone resorption by osteoclasts [68], and could therefore be a 
downstream target of cellular events such as extracellular matrix adhesion-mediated signaling, changes 
in cell shape and responses to local paracrine environments. A second transcription factor, osterix, has 
been described and has been suggested to play a key role downstream of RUNX-2 in which its 
expression is necessary for the ongoing differentiation within in the osteogenic pathway (versus sifting 
to a chondrogenic pathway) [69]. In an in vitro study, Misaski et al., showed that human mesenchymal 
stems cells grown on titanium surfaces with a nanoetched topography had elevated RUNX-2 and Type 
I Collagen expression and specifically increased the expression of alkaline phosphatase, a key enzyme 
involved in the control of biomineralization at the implant surface [70]. Upregulation of osterix and 
BSP was noted on alumina coated titanium surfaces with a nanometer level topography, relative to 
surfaces with just micrometer-level surface features. Human mesenchymal stem cells were grown over 
a 28 day period and demonstrated specific response to the etched titanium surfaces [71–73].  Int. J. Mol. Sci. 2010, 11                 
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The promotion of osteoblast attachment and differentiation has been evaluated on various implant 
surfaces using a variety of cell culture and animal models [2,74,75]. For instance, the expression of 
matrix related proteins such as alkaline phosphatase (an enzyme with a role in biomineralization) and 
Type I collagen were enhanced on sand blasted and acid etched cpTi surfaces [76] The mechanism by 
which topography influences osteoblast differentiation appears to be mediated by the protein kinase A 
and PL-A2 pathway [77], and by integrin mediated signaling pathways [74,78,79]. The topography 
also influences subsequent expression of osteoblast-mediated cytokines and growth factors. 
Osteosarcoma cells (MG-63) grown on roughened surfaces had increased TGF-Beta and IL-1beta [80] 
in which a prostaglandin mediated response was described leading to decreased proliferation on 
characterized rougher surfaces with an increase in cellular phenotypic markers of differentiation (ALP 
activity, osteocalcin). While these observations demonstrate cellular responses of osteoblasts to the 
matrix absorbed onto the surface of an implant, they do not provide information on the role the surface 
(and the resultant matrix topography) on initial platelet adhesion/activation events and subsequent 
alterations of osteoblast cell shape and differentiation. It may be possible that the implant topography 
may lead to enhanced differentiation of osteoblasts through alterations in transcriptional regulation or 
gene expression of key osteogenic factors as a result of changes in cell shape due to interaction with 
the implant surface microtopography [81]. 
5. Implant Micro-Retentive Features: Surface Roughness by Blasting/Etching 
Various studies have also addressed the issue of surface roughness through various means of grit 
blasting followed by a surface etching or coating procedure. This has included titanium plasma spray 
(TPS) [35], abrasion (TiO2 blasting or use of soluble abrasives) combinations of blasting and etching 
(e.g., Al2O3 with H2SO4/HCL) [35], thin apatite coating [82] or sintered beads [83]. Commercially 
available roughened surfaces using the large grit blasted and acid etched surface (e.g., Straumann’s 
SLA surface) having both laboratory and clinical evidence of elevated success rates in areas of the 
posterior maxilla [84–88]. The role of the roughened surface is complex since the actual strength of 
bone contact against the titanium oxide surface is quite low (4 MPa or less); weak enough that without 
the surface topography (e.g., electropolished surfaces) little bone contact occurs [37].  A  further 
modification of the SLA grit blasted and dual acid etched surface has recently been described [89]. In 
this procedure, the same surface roughening process occurs but there is a nitrogen atmosphere used to 
control the rate and formation of the oxide surface by attempting to reduce hydrocarbon contamination 
of the implant surface.  
Various titanium surfaces have utilized surface roughness created either though a grit blasting and 
etching procedure or blasting of the surface alone by using tightly controlled conditions in order to 
obtain a pre-defined optimal surface topography. One such optimization criteria has been 
proposed [90,91]. This criteria suggests that an implant surface has an optimal balance between pore 
size on the surface (pore sizes of 1–5 µm diameter and 1–5 µm in depth) which optimizes the shear 
strength of the individual bone in-growth into anyone pit with the need to have as many “pits” on the 
surface as possible [15,34]. A further modification of the titanium dioxide grit blasted surface is then 
performed with a mild hydrofluoric acid etching to create surface pitting on the blasted surface. The 
optimization criteria calls for maintaining the macroroughness derived from the blasting process Int. J. Mol. Sci. 2010, 11                 
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followed by the surface etching to influence the secondary osseointegration process (the process of 
wound healing following implant placement). Masaki et al. and Isa et al. used a human mesenchymal 
cell culture model and demonstrated there was a rapid increase in expression of key genes involved in 
the differentiation of bone unique to the fluoride modified and etched titanium surface that was not 
evident on blasted surface alone or a comparison group of large grit and dual acid etched 
surfaces [70,78]. In a follow-up study, Cooper et al. demonstrated that the same titanium surfaces also 
increases expression of bone adhesion and increased expression of bone sialoprotein, osteopontin and 
other bone-specific proteins critical to an accelerated bone adaptation to the implant surface [92].  
Currently there are two main, but inter-related approaches being evaluated to enhance bone 
adaption to dental implant surfaces. Both approaches are designed to improve the adaptation of 
trabecular bone. The two approaches involve either the addition of biological mediators to the implant 
surface (e.g., cell adhesion or bioactive peptides, growth factors, etc.) or creation of reproducible 
nanoscale surface features.  
The addition of bioactive peptides has a long and rich history in biomaterials research with 
strategies to covalently add either cell adhesion peptides or growth factors to the implant surface and 
thus use the implant as a local drug delivery device. The manner in which the fibrin scaffold is 
manipulated is one key to the future of implant surface technology [93–95]. Approaches to modifying 
the titanium oxide surface utilizes placement of various configurations of the commonly known 
recognition peptide sequences for cell adhesive integrins cell membrane associated matrix binding 
receptors (a tripeptide sequence of Arg-Gly-Asp or “RGD”) on the surface of an implant surface. This 
RGD sequence mediates cell adhesion and is present in a number of extracellular matrix proteins (e.g., 
fibrin, collagen, fibronectin, vitronectin, osteopontin and bone sialoprotein). Obviously, many 
mesenchymal cells possess integrin receptors and thus the adhesion to an RGD coated surface may be 
rather non-specific but a number of groups are attempting to regulate the type of cell adhesion that 
occurs by modulating the sequence of proteins in the linker region (the region of protein attaching the 
RGD sequence to the metal substrate) as well as exploring various means to attach adhesion sequences 
(e.g., repeated regions of RGD sequence) through covalent attachment to the surface of the 
implant  [59,79,96–107]. Work has focused on determining the optimal density of RGD adhesion 
peptides on an experimental implant surface to elicit osteoblast growth and differentiation [99].  
Osteoblastic cells interact both with the matrix, through the RGD dependent pathways, but also to 
the surface contours of the surface. This property of “contact guidance” is an important part of 
understanding the behavior of how pre-osteoblasts interact with the complex fibrin/platelet scaffold. 
There are a number of elegant in vitro and  in vivo studies which document the importance of   
not just the roughness of an implant surface but the effect of the direction of the pattern   
(or epitaxis)  [108–111]. These studies demonstrate that fibroblasts and osteoblasts are capable of 
recognizing repeated surface features (e.g., lines, grooves and other defects created in machining). 
Cells appear to align and grow in a directional pattern directed by the surface features of the 
substratum  [112]. Highly repeated, nanoscale surface features are capable of being formed with 
inexpensive photolithographic approaches. These repeating surface features are capable of combining 
properties of surface chemistry (e.g., surface energy) with biological attachment of adhesion/matrix 
peptides [112,113]. Similar photolithographic approaches have been used to create repeated patterns to 
generate controlled alternating domains of N-(2-aminoethyl)-3-aminopropyl-trimethoxysilane (EDS) Int. J. Mol. Sci. 2010, 11                 
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and dimethyldichlorosilane (DMS) as a means to control the adsorption of naturally occurring RGD 
adhesive proteins in serum (especially vitronectin) [101,103]. In this way, a bioactive surface may be 
generated that uses the natural adhesive proteins in the blood plasma at the time of implant placement. 
Obviously, there are still multiple issues of bioavailability and biological stability of these peptides 
that are being worked out but promise holds with such techniques.  
The other direction for manipulating biological responses is to create topographical surface features 
at the nanoscale level on the titanium oxide surface. Relevant nanometer (10
−9 m) scale features 
typically means in the range of 1–100 nm in dimension. The interest in this area of research is that the 
conventional Newtonian properties of materials are very different for a nanomaterial (e.g., increased 
number of atoms at the surface, surface grain boundaries, enhanced surface energy and surface area, 
electron delocalization, etc.) [48,71–73,114–117]. At the nanoscale level molecular interactions with 
the surface can be targeted to create specific cell level responses. For instance, work done with 
nanophase ceramics more than a decade ago demonstrated a specific increase in osteoblast cell 
adhesion, differentiation and matrix expression on surfaces with a 60 nm grain size or less [118]. If the 
grain size is 70 nm or greater the specific biological effects were lost. Further studies suggested this 
effect may be related to protein orientation to the nanophase structures and specifically the mode of 
orientation of adhesion proteins such as vitronectin to the grain boundaries which in turn alters 
osteoblast adhesion and shape; both critical to formation of bone [41,116,119–122].  
The use of dental implants to replace missing teeth has made rapid progressions over the past 
twenty five years. Ongoing developments in the area of surface technology are aimed at enhancing 
tissue/surface interactions and to potentially use the expanding knowledge regarding the immune 
response, especially the role of the highly complex macrophage family of immune affecter cells. As 
our knowledge of these complex pathways is incomplete so is our ability to currently predict the 
biological responses to changes in surface properties. As the disciplines of immunology continues to 
understand the wound healing process, biomaterials development plays a complementary role as an 
interdisciplinary approach to developing implant surfaces that mimic and promote accelerated wound 
healing processes. All of these ongoing developments have a central goal of enhancing patient care.  
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